The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
Abstract
The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor of the ErbB family that is abnormally activated in many epithelial tumors. Receptor activation leads to recruitment and phosphorylation of several downstream intracellular substrates, leading to mitogenic signaling and other tumor-promoting cellular activities. In human tumors, receptor overexpression correlates with a more aggressive clinical course. Taken together, these observations indicate that the EGFR is a promising target for cancer therapy. Monoclonal antibodies directed at the ligand-binding extracellular domain and low–molecular weight inhibitors of the receptor’s tyrosine kinase are currently in advanced stages of clinical development. These agents prevent ligand-induced receptor activation and downstream signaling, which results in cell cycle arrest, promotion of apoptosis, and inhibition of angiogenesis. They also enhance the antitumor effects of chemotherapy and radiation therapy. In patients, anti-EGFR agents can be given safely at doses that fully inhibit receptor signaling, and single-agent activity has been observed against a variety of tumor types, including colon carcinoma, non–small-cell lung cancer, head and neck cancer, ovarian carcinoma, and renal cell carcinoma. Although antitumor activity is significant, responses have been seen in only a minority of the patients treated. In some clinical trials, anti-EGFR agents enhanced the effects of conventional chemotherapy and radiation therapy. Ongoing research efforts are directed at the selection of patients with EGFR-dependent tumors, identification of the differences among the various classes of agents, and new clinical development strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Olayioye, M. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,434
Signal Transduction through MAP Kinase Cascades
(1998) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60765-4 · Cited by 1,759
Prenzel, N., Zwick, E., Daub, H., Leserer, M., Abraham, R., Wallasch, C., & Ullrich, A. (1999) · Nature · doi:10.1038/47260 · Cited by 1,504
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Self-citationLevels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
Grandis, J. R., Melhem, M. F., Gooding, W. E., Day, R., Holst, V. A., Wagener, M. M., Drenning, S. D., & Tweardy, D. J. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.824 · Cited by 1,113
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001
Baselga, J. M., Norton, L., Albanell, J., Kim, Y. M., & Mendelsohn, J. M. (1998) · PubMed · Cited by 996
Self-citationCiardiello, F., Caputo, R., Bianco, R., Damiano, Pomatico, G., De Placido, S., Bianco, A. R., & Tortora, G. (2000) · PubMed · Cited by 943
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
Nishikawa, R., Ji, X. D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., & Huang, H. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.16.7727 · Cited by 936
BindingDB (2025) · PubMed · doi:10.7270/q2dr317m · Cited by 843
Petit, A. M. V., Rak, J. W., Hung, M., Rockwell, P., Goldstein, N. I., FENDLY, B. M., & Kerbel, R. S. (1997) · Europe PMC (PubMed Central) · Cited by 836
Kawamoto, T., Sato, J. D., Le, A., Polikoff, J., Sato, G. H., & Mendelsohn, J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.5.1337 · Cited by 791
Self-citationGoldstein, N. I., Prewett, M. C., Zuklys, K., Rockwell, P., & Mendelsohn, J. M. (1995) · PubMed · Cited by 785
Self-citationSirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I., & Kris, M. G. (2000) · PubMed · Cited by 761
Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D’Andrea, G., Seidman, A., Norton, L., Gunnett, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.904 · Cited by 741
Self-citationChan, T. O., Rittenhouse, S. E., & Tsichlis, P. N. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.965 · Cited by 737
Alroy, I., & Yarden, Y. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00412-2 · Cited by 714
Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J., Radinsky, R., & Dinney, C. P. (1999) · PubMed · Cited by 647
Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Fontanini, G., Cuccato, S., Placido, S. D., Bianco, A. R., & Tortora, G. (2001) · PubMed · Cited by 643
Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors.
Moscatello, D. K., Holgado-Madruga, M., Godwin, A. K., Ramirez, G., Gunn, G. R., Zoltick, P. W., Biegel, J. A., Hayes, R. L., & Wong, A. J. (1995) · PubMed · Cited by 637
Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Cohen, E. E. W., Rosen, F., Stadler, W. M., Recant, W., Stenson, K., Huo, D., & Vokes, E. E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.051 · Cited by 610
Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., & Arteaga, C. L. (2001) · PubMed · Cited by 597
Moasser, M. M., Basso, A., Averbuch, S. D., & Rosen, N. X. (2001) · PubMed · Cited by 555
Bruns, C. J., Solórzano, C. C., Harbison, M. T., Ozawa, S., Tsan, R. Z., Fan, D., Abbruzzese, J. L., Traxler, P. M., Buchdunger, E., Radinsky, R., et al. (2000) · PubMed · Cited by 532
Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Mascaro, J. M., Herbst, R. S., LoRusso, P. M., Rischin, D., Sauleda, S., Gee, J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.110 · Cited by 528
Self-citationIn vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody.
Milas, L., Mason, K. A., Hunter, N. R., et al. (2000) · PubMed · Cited by 503
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
Lewis, G. D., Figari, I., Fendly, B., Lee Wong, W., Carter, P., Gorman, C., & Shepard, H. M. (1993) · Cancer Immunology, Immunotherapy · doi:10.1007/bf01518520 · Cited by 498
Combinatorial chemoprevention of intestinal neoplasia
Torrance, C. J., Jackson, P. E., Montgomery, E., Kinzler, K. W., Vogelstein, B., Wissner, A., Nunes, M., Frost, P., & Discafani, C. M. (2000) · Nature Medicine · doi:10.1038/79534 · Cited by 493
Rusch, V. W., Baselga, J. M., Cordon‐Cardo, C., Orazem, J. P., Zaman, M., Hoda, S. A., McIntosh, J., Kurie, J. M., & Dmitrovsky, E. (1993) · PubMed · Cited by 482
Self-citationRobert, F., Ezekiel, M. P., Spencer, S. A., Meredith, R. F., Bonner, J. A., Khazaeli, M. B., Saleh, M. N., Carey, D., LoBuglio, A. F., Wheeler, R. H., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3234 · Cited by 474
Fan, Z., Baselga, J. M., Masui, H., & Mendelsohn, J. M. (1993) · PubMed · Cited by 456
Self-citationGill, G. N., Kawamoto, T., Cochet, C., Le, A., Sato, J. D., Masui, H., McLeod, C., & Mendelsohn, J. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42857-2 · Cited by 455
Self-citationMasui, H., Kawamoto, T., Sato, J. D., Wolf, B., Sato, G., & Mendelsohn, J. (1984) · Journal of Urology · doi:10.1016/s0022-5347(17)50005-1 · Cited by 446
Self-citationFry, D. W., Bridges, A. J., Denny, W. A., Doherty, A., Greis, K. D., Hicks, J. L., Hook, K. E., Keller, P. R., Leopold, W. R., Loo, J. A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.12022 · Cited by 418
Targeting the epidermal growth factor receptor for cancer therapy.
Mendelsohn, J. M. (2002) · PubMed · Cited by 414
Self-citationBaselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. H., & Mendelsohn, J. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.16.1327 · Cited by 411
Self-citationLiu, D., Ghiso, J. A. A., Estrada, Y., & Ossowski, L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00072-7 · Cited by 392
Wu, X., Fan, Z., Masui, H., Rosen, N., & Mendelsohn, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117871 · Cited by 381
Self-citationKlapper, L. N., Waterman, H., Sela, M., & Yarden, Y. (2000) · PubMed · Cited by 351
Ciardiello, F., Bianco, R., Damiano, V., Lorenzo, S. D., Pepe, S., Placido, S. D., Fan, Z., Mendelsohn, J. M., Bianco, A. R., & Tortora, G. (1999) · PubMed · Cited by 332
Self-citationYang, X., Jia, X., Corvalan, J. R. F., Wang, P., Davis, C., & Jakobovits, A. (1999) · PubMed · Cited by 328
EGF mutant receptor vIII as a molecular target in cancer therapy.
Kuan, C. T., Wikstrand, C. J., & Bigner, D. D. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080083 · Cited by 323
Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion.
Lal, A., Glazer, C. A., Martinson, H. M., Friedman, H. S., Archer, G. E., Sampson, J. H., & Riggins, G. J. (2002) · PubMed · Cited by 311
Shin, D. M., Donato, N. J., Perez-Soler, R., Shin, H. J. C., Wu, J. Y., Zhang, P. G. Y., Lawhorn, K., Khuri, F. R., Glisson, B. S., Myers, J. N., et al. (2001) · PubMed · Cited by 298
Self-citationCrombet, T., Osorio, M., Cruz, T., Roca, C., del Castillo, R., Mon, R., Iznaga-Escobar, N., Figueredo, R., Koropatnick, J., Renginfo, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.089 · Cited by 296
Fan, Z., Lu, Y., Wu, X., & Mendelsohn, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47026-3 · Cited by 283
Self-citationPeng, D., Fan, Z., Yang, L., DeBlasio, T., Scher, H. I., & Mendelsohn, J. M. (1996) · PubMed · Cited by 280
Self-citationNormanno, N., Campiglio, M., De Luca, A., Somenzi, G., Maiello, M., Ciardiello, F., Gianni, L., Salomon, D. S., & Menard, S. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf020 · Cited by 273
Albanell, J., Codony‐Servat, J., Rojo, F., Campo, J. M. D., Sauleda, S., Anido, J., Raspall, G., Giralt, J., Roselló, J., Nicholson, R. I., et al. (2001) · PubMed · Cited by 273
Self-citationEmployment of the Epidermal Growth Factor Receptor in Growth Factor–Independent Signaling Pathways
Carpenter, G. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.4.697 · Cited by 272
Anido, J., Matar, P., Albanell, J., Guzmán, M., Rojo, F., Arribas, J., Averbuch, S. D., & Baselga, J. M. (2003) · PubMed · Cited by 264
Self-citationAboud-Pirak, E., Hurwitz, E., Pirak, M., Bellot, F., Schlessinger, J., & Sela, M. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.20.1605 · Cited by 231
Wu, X., Rubin, M., Fan, Z., DeBlasio, T., Soos, T. J., Koff, A., & Mendelsohn, J. M. (1996) · PubMed · Cited by 228
Self-citationBusse, D., Doughty, R. S., Ramsey, T. T., Russell, W. E., Price, J. O., Flanagan, W. M., Shawver, L. K., & Arteaga, C. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.10.6987 · Cited by 205
Bos, M., Mendelsohn, J. M., Kim, Y. M., Albanell, J., Fry, D. W., & Baselga, J. M. (1997) · PubMed · Cited by 199
Self-citationChemoprevention of Breast Cancer: A Model for Change
Jordan, V. C., & Morrow, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.1.1 · Cited by 197
Perez-Soler, R. (2001) · Medical Entomology and Zoology · Cited by 189
O‐charoenrat, P., Modjtahedi, H., Rhys‐Evans, P., Court, W. J., Box, G., & Eccles, S. A. (2000) · PubMed · Cited by 159
Rodeck, U., Herlyn, M., Herlyn, D., Molthoff, C. F. M., Atkinson, B., Varello, M. A., Steplewski, Z., & Koprowski, H. (1987) · PubMed · Cited by 150
Arteaga, C. L., Ramsey, T. T., Shawver, L. K., & Guyer, C. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.37.23247 · Cited by 144
Clinical experience with CD64-directed immunotherapy. An overview
Curnow, R. T. (1997) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620050435 · Cited by 141
Naramura, M., Gillies, S. D., Mendelsohn, J. M., Reisfeld, R. A., & Mueller, B. M. (1993) · Cancer Immunology Immunotherapy · doi:10.1007/bf01518458 · Cited by 141
Self-citationNuclear targeting of Bax during apoptosis in human colorectal cancer cells
Mandal, M., Adam, L., Mendelsohn, J. M., & Kumar, R. (1998) · Oncogene · doi:10.1038/sj.onc.1202020 · Cited by 137
Self-citationLiu, B., Fang, M., Schmidt, M., Lü, Y., Mendelsohn, J. M., & Fan, Z. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1201 · Cited by 128
Self-citationLichtner, R. B., Menrad, A., Sommer, A., Klar, U., & Schneider, M. R. (2001) · PubMed · Cited by 121
Azémar, M., Schmidt, M., Arlt, F., Kennel, P., Brandt, B., Papadimitriou, A., Groner, B., & Wels, W. S. (2000) · International Journal of Cancer · Cited by 104
Ciardiello, F., Caputo, R., Troiani, T., Borriello, G., Kandimalla, E. R., Agrawal, S., Mendelsohn, J. M., Bianco, A. R., & Tortora, G. (2001) · International Journal of Cancer · doi:10.1002/ijc.1335 · Cited by 89
Self-citationYamazaki, H., Kijima, H., Abe, Y., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.8.581 · Cited by 85
O‐charoenrat, P., Rhys‐Evans, P. H., Court, W. J., Box, G., & Eccles, S. A. (1999) · Clinical & Experimental Metastasis · doi:10.1023/a:1006751016860 · Cited by 76
Dw, F. (2000) · PubMed · Cited by 72
ZD1839, AN EPIDERMAL GROWTH FACTOR TYROSINE KINASE INHIBITOR SELECTED FOR CLINICAL DEVELOPMENT
Woodburn, J. R., Barker, A. J., Gibson, K. H., et al. (1997) · Journal of Immunotherapy · doi:10.1097/00002371-199709000-00044 · Cited by 66
Goldstein, J., Graziano, R. F., Sundarapandiyan, K., Somasundaram, C., & Deo, Y. M. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.2.872 · Cited by 31
Negri, D. R. M., Tosi, E., Valota, O., et al. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.435 · Cited by 29
Giaccone, G., Gonzales-Larriba, J. L., Smit, E. F., et al. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)80594-3 · Cited by 17
Tamura, T., Nakagawa, K., Fukuoka, M., Kudoh, S., Yoshimura, N., Negoro, S., Takeda, K., & Kelly, H. (2000) · Lung Cancer · doi:10.1016/s0169-5002(00)80229-9 · Cited by 16
Franke, H. R., & Vermes, I. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00293-9 · Cited by 13
Cited by
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., & Adjei, A. A. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60735-0 · Cited by 3,908
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Metadata
- Authors
- Mendelsohn, J., & Baselga, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-07-15
- Volume
- 21
- Issue
- 14
- Pages
- 2787-2799
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2039633811
- Cited by
- 1,255
- References
- 83
- FWCI
- 45.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.